Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced preclinical research from its ongoing in vivo gene editing program targeting hepatitis B virus (HBV) has been published online in Molecular Therapy.
- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced preclinical research from its ongoing in vivo gene editing program targeting hepatitis B virus (HBV) has been published online in Molecular Therapy.
- Our data suggest that LNP-delivered ARCUS mRNA is worth further exploration as a possible functional cure for chronic hepatitis B, said Derek Jantz, Chief Scientific Officer and Co-founder of Precision BioSciences.
- Precisions gene editing program for chronic hepatitis B is designed to apply ARCUS to knock out persistent cccDNA and inactivate integrated hepatitis B genomes, potentially achieving durable HBsAg loss and functional cure.
- ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery and control in mind.